New Report Praises Advances in Cancer Treatment for Preventing Millions of Deaths

A new report has highlighted that the rate of death due to cancer in America has steadily declined in the last few decades. As of January 2022, more than 18 million individuals who have survived cancer live in America. This is a new record, especially if one compares the figures against the 3 million survivors recorded in the U.S. in 1971. Researchers predict that by 2040, this number will have reached 24 million.

The report, which was released late last month by the American Association for Cancer Research, notes that the number of individuals who survived after receiving their diagnosis had been consistently rising. This, experts believe, is because of the significant advances made in the diagnosis and treatment of cancer.

The report states that remarkable advancements have been made in the field these last 10 years, leading to great improvements in the detection, diagnosis, treatment and prevention of cancer. Improved effectiveness of treatments against the most common types of cancer, including prostate, colorectal, breast and lung, have also helped improve the five-year rate of survival for all cancers, moving to about 70% in the period between 2011 and 2017 from less than 50% in the 70s.

The report added that the reduction in the rate of smoking also played a role in this decrease, alongside the new cancer therapies approved by regulatory agencies to combat the illness. In figures, more than 3.5 million deaths have been avoided since the early ‘90s.

In addition, federal investments in medical research are said to have sped up the ability to alter the outcomes of patients.

In a news release, Dr. Lisa M. Coussens, the president of the American Association for Cancer Research, stated that basic discoveries from research had driven the astounding advancements that had been observed in the cancer field in the recent years.

Coussens added that immunotherapy, targeted treatments and other new therapy approaches that are applied clinically all stemmed from foundational discoveries in basic sciences. She noted that investment in cancer science and support for science education at every level was necessary to accelerate progress and drive the next wave of discoveries.

Despite these advancements, however, it is expected that roughly 600,000 individuals will succumb to cancer this year.

In the report, the American Association for Cancer Research forecasts that by 2040, there will be about 2.3 million new cancer cases. It adds that while the number is high, 40% of these cases are attributed to preventable causes.

With entities such as QSAM Biosciences Inc. (OTCQB: QSAM) also focused on delivering cutting-edge cancer therapies, the loss of lives to different cancers is likely to keep reducing as the years go by.

NOTE TO INVESTORS: The latest news and updates relating to QSAM Biosciences Inc. (OTCQB: QSAM) are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork.


Select A Month

Official NewsWire Relationships

BIO Informa DGE Dynamic Global Events DTC Healthcare Conference Kiasco Reasearch Nexus Conferences Octane

BioMedWire Currently Accepts



Bitcoin Cash

Bitcoin Cash





USD Coin

USD Coin

Contact us: 415.949.5050